ISAM-140

ISAM-140
Names
	IUPAC names (±)-Isopropyl 4-(Furan-2-yl)-2-methyl-1,4-dihydrobenzo-[4,5]imidazo[1,2-a]pyrimidine-3-carboxylate, 4-(2-Furanyl)-4,10-dihydro-2-methyl-pyrimido[1,2-a]benzimidazole-3-carboxylic acid 1-methylethyl ester
	Other names ISAM140
Identifiers
CAS Number	932191-62-3 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL3787197;
ChemSpider	12904393 ;
IUPHAR/BPS	11223;
PubChem CID	17198004;
	InChI InChI=1S/C19H19N3O3/c1-11(2)25-18(23)16-12(3)20-19-21-13-7-4-5-8-14(13)22(19)17(16)15-9-6-10-24-15/h4-11,17H,1-3H3,(H,20,21) Key: NYHLRBMDXQBOIB-UHFFFAOYSA-N;
	SMILES CC1=C(C(N2C3=CC=CC=C3N=C2N1)C4=CC=CO4)C(=O)OC(C)C;
Properties
Chemical formula	C19H19N3O3
Molar mass	337.37
Appearance	White solid
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

百度（记者苏莉通讯员向行军）

ISAM-140 is a selective non-xanthinic adenosine A_2B receptor antagonist. Discovered in 2016,^[1] it has a K_i of 3.49 nM on the A_2B receptor and >1000-fold selectivity with respect to the other three adenosine receptor subtypes. It has been shown to help the immune system to attack cancer cells in in vitro assays by rescuing T and NK cell proliferation, cytokine release, and TIL infiltration.^[2]

References

^ El Maatougui, Abdelaziz; Azuaje, Jhonny; González-Gómez, Manuel; Miguez, Gabriel; Crespo, Abel; Carbajales, Carlos; Escalante, Luz; García-Mera, Xerardo; Gutiérrez-de-Terán, Hugo; Sotelo, Eddy (2025-08-04). "Discovery of Potent and Highly Selective A 2B Adenosine Receptor Antagonist Chemotypes". Journal of Medicinal Chemistry. 59 (5): 1967–1983. doi:10.1021/acs.jmedchem.5b01586. ISSN 0022-2623. PMID 26824742.
^ Tay, Apple Hui Min; Prieto-Díaz, Rubén; Neo, Shiyong; Tong, Le; Chen, Xinsong; Carannante, Valentina; ?nfelt, Bj?rn; Hartman, Johan; Haglund, Felix; Majellaro, Maria; Azuaje, Jhonny (2025-08-04). "A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models". Journal for ImmunoTherapy of Cancer. 10 (5): e004592. doi:10.1136/jitc-2022-004592. ISSN 2051-1426. PMC 9115112. PMID 35580926.